(S)-Crizotinib

• CAT Number: R030609
• CAS Number: 1374356-45-2
• Molecular Formula: C21H22Cl2FN5O
• Molecular Weight: 450.34
• Purity: ≥95%
• Synonyms: 3-[(1S)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
• Target: Apoptosis
• Storage: Desiccate at RT
• IUPAC Name: 3-[(1S)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
• InChI: InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m0/s1
• InChIKey: KTEIFNKAUNYNJU-LBPRGKRZSA-N
• SMILES: C[C@@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

(S)-Crizotinib（Cat No.:R030609）is the enantiomer of Crizotinib, a selective tyrosine kinase inhibitor targeting ALK, ROS1, and MET proteins involved in cancer progression. While (R)-Crizotinib is the active form used clinically for treating ALK-positive non-small cell lung cancer (NSCLC) and ROS1-positive cancers, (S)-Crizotinib serves as a critical research tool. It is used to study enantiomeric selectivity, pharmacodynamics, and the structure-activity relationship of tyrosine kinase inhibitors. Investigations involving (S)-Crizotinib contribute to understanding drug efficacy, resistance mechanisms, and the development of more targeted cancer therapies.